Endothelin in cardiovascular control: the role of endothelin antagonists.
- 1 January 1999
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Hypertension Reports
- Vol. 1 (1), 79-87
- https://doi.org/10.1007/s11906-999-0077-7
Abstract
Endothelin (ET) is a potent vasoconstrictor associated with various cardiovascular diseases. ET mediates its effects through ET receptors on vascular smooth muscle cells as well as on the vascular endothelium. Furthermore, a neurotransmitter role for ET has been suggested on the basis of experimental and human in vivo studies. ET antagonists are potent tools for studying the effects of ET and its receptors. They have been widely used in vitro and in experimental models of cardiovascular disease, where ET levels are elevated and reactivity to ET is altered. Promising clinical trials in hypertension, coronary artery disease, and congestive heart failure are discussed in this review. Different forms of renal failure are associated with markedly increased ET levels, and ET antagonists experimentally improve renal function in these models. Extrapolating from experimental and first clinical experience, ET antagonists could be useful in the treatment of hypertension, coronary artery disease, congestive heart failure, and renal failure, especially in combination with other drugs, ie, angiotensin converting enzyme inhibitors. The inhibition of ET-induced stimulation of nociception allows for speculation that ET antagonists might even have analgesic properties.Keywords
This publication has 91 references indexed in Scilit:
- ET A Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive HypertensionHypertension, 1998
- Dose‐ and time‐dependency of the dilator effects of the endothelin antagonist, BQ‐123, in the human forearmBritish Journal of Clinical Pharmacology, 1997
- Characterization of Contractile Endothelin and Angiotensin Receptors in Human Resistance Arteries: Evidence for Two Endothelin and One Angiotensin ReceptorBiochemical and Biophysical Research Communications, 1994
- Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive modelLife Sciences, 1993
- Is endothelin involved in the pathogenesis of hypertension?Hypertension, 1993
- ET-1 released histamine from guinea pig pulmonary but not peritoneal mast cellsBiochemical and Biophysical Research Communications, 1992
- Different Mobilization of Calcium in Endothelin-1 -Induced Contractions in Human Arteries and Veins: Effects of Calcium AntagonistsJournal of Cardiovascular Pharmacology, 1990
- Raised plasma endothelin-I concentration following cold pressor testBiochemical and Biophysical Research Communications, 1990
- Endothelin enhances adrenergic vasoconstriction in perfused rat mesenteric arteriesBiochemical and Biophysical Research Communications, 1989
- Endothelin is a positive inotropic agent in human and rat heart in, vitroBiochemical and Biophysical Research Communications, 1989